Internal Medicine, Rheumatology · Mountain Brk, AL
NPI
1336439595
Since 2011
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
4
Medicare group memberships
Hospitals
0
Hospital affiliations
12 Office Park Cir
Mountain Brk, AL, 35223
Phone (205) 933-0320
Groups this clinician bills Medicare through
Medicare paid, 2024
$365K
38,461 services
Medicare patients, 2024
301
Average age 70
Drug cost, 2024
$6.5M
4,334 prescriptions
Company payments, 2025
$33K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Matthew Mullen was code J1602 (injection, golimumab, 1 mg, for intravenous use), 3,750 times for 12 patients. In total Matthew Mullen billed 38,461 services in 55 codes, and Medicare paid $365K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 3,750 | 12 | $8.83 | $33K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,000 | 18 | $0.10 | $102 |
| J0897 Injection, denosumab, 1 mg | Office | 960 | 16 | $21.43 | $21K |
| 99214 Office E&M - Established | Office | 184 | 158 | $88.45 | $16K |
| 99214 Office E&M - Established | Facility | 123 | 103 | $55.53 | $6,830 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 101 | 16 | $0.75 | $75.92 |
| 96413 Chemotherapy Administration | Office | 70 | 32 | $88.42 | $6,189 |
| 99215 Office E&M - Established | Office | 61 | 57 | $127.57 | $7,782 |
| 96365 Intravenous Infusion, Hydration | Office | 52 | 21 | $43.05 | $2,239 |
| 96415 Chemotherapy Administration | Office | 43 | 15 | $19.32 | $831 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 37 | 33 | $10.74 | $397 |
| 83516 Immunoassay | Office | 30 | 14 | $11.04 | $331 |
| 96372 Injection Administration | Office | 27 | 22 | $10.25 | $277 |
| 20610 Joint Injection | Office | 27 | 23 | $51.81 | $1,399 |
| 85652 Clinical Chemistry | Office | 23 | 23 | $2.65 | $60.95 |
By year: 2022 $28K for 451 services; 2023 $27K for 444 services; 2024 $365K for 38,461 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83516 Immunoassay | 30 | 14 | $11.04 | $331 |
| 85652 Clinical Chemistry | 23 | 23 | $2.65 | $60.95 |
| 85025 Blood Count | 19 | 19 | $7.61 | $145 |
| 86431 Immunoassay | 14 | 14 | $5.56 | $77.84 |
| 86200 Immunoassay | 13 | 13 | $12.28 | $160 |
Medicare prescription drug claims, 2024
In 2024, the drug Matthew Mullen prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 446 prescriptions and refills. In total Matthew Mullen wrote 4,334 Medicare prescriptions that cost $6.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 446 | 769 | 152 | $15K |
| Hydroxychloroquine Sulfate Generic | 425 | 980 | 164 | $29K |
| Prednisone Generic | 315 | 500 | 112 | $2,293 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 237 | 237 | 66 | $5,082 |
| Tramadol Hcl Generic | 165 | 166 | 45 | $885 |
| Gabapentin Generic | 153 | 256 | 51 | $1,871 |
| Duloxetine Hcl Generic | 146 | 354 | 59 | $4,461 |
| Humira(Cf) Pen Adalimumab | 130 | 140 | 22 | $983K |
| Enbrel Sureclick Etanercept | 104 | 111 | 19 | $774K |
| Pregabalin Generic | 90 | 108 | 18 | $1,909 |
| Celecoxib Generic | 89 | 128 | 28 | $2,544 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 87 | 88 | 17 | $3,433 |
| Cosentyx Sensoready (2 Pens) Secukinumab | 80 | 80 | Under 11 | $737K |
| Allopurinol Generic | 79 | 208 | 31 | $1,119 |
| Cyclobenzaprine Hcl Generic | 73 | 83 | 26 | $623 |
Brand drugs: - claims; generic drugs: 3,292 claims; opioid claims: 526.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Matthew Mullen $33K ($33K in general payments such as food, travel and fees) from 16 companies. The largest payer was Janssen Biotech, Inc. with $30K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 42 | $30K |
| Abbvie Inc. ABBV | 23 | $612 |
| Novartis Pharmaceuticals Corporation NVS | 15 | $536 |
| Genzyme Corporation SNY | 9 | $466 |
| Amgen Inc. AMGN | 17 | $315 |
| UCB, Inc. UCB.BR | 17 | $285 |
| GlaxoSmithKline, LLC. GSK | 11 | $259 |
| Pfizer Inc. PFE | 12 | $174 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $150 |
| Mallinckrodt Hospital Products Inc. | 4 | $115 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.